文献速递生殖医学

在长方案促性腺激素释放激素激动剂方案中,卵巢刺激女性添加绒促性素β至促卵泡激素δ的随机对照首次患者试验

A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
PubMed 文献 · Hum Reprod · 2022-01-01

这项安慰剂对照双盲随机试验在五个欧洲国家纳入620名30-42岁、AMH 5-35 pmol/l的女性,比较在长GnRH激动剂方案中每日个体化促卵泡激素δ基础上添加安慰剂或1、2、4、8、12 μg绒促性素β的效果。结果显示添加绒促性素β减少了中等大小卵泡数、获卵数和优质囊胚数,持续妊娠率在促卵泡激素δ单药组为每启动周期43%、每移植49%。

要点

  • 添加绒促性素β后中等大小(12-17 mm)卵泡数及获卵数较单用促卵泡激素δ减少。
  • 优质囊胚数在促卵泡激素δ组为3.3,绒促性素β各组为2.1-3.0。
  • 绒促性素β各组卵巢过度刺激综合征发生率2.0-10.3%,低于单药组的11.5%。

核心结论

  • 在所研究的剂量下,添加绒促性素β减少了中等大小卵泡数及包括获卵数和囊胚数在内的下游参数。

研究设计与样本

  • 安慰剂对照、双盲、随机试验(RAINBOW),在五个欧洲国家开展,按中心和年龄(30-37岁和38-42岁)分层随机。
  • 共620名30-42岁、AMH 5-35 pmol/l的女性按等比例随机分配至六个治疗组,619名受试者开始治疗。

主要发现

  • demographics特征在六组间可比,总体平均年龄35.6±3.3岁、体重65.3±10.7 kg、AMH 15.3±7.0 pmol/l。
  • 周期取消发生率(范围0-2.9%)、促卵泡激素δ总剂量(平均112 μg)和刺激持续时间(平均10天)在各组间相似。
  • 刺激第6天各组卵泡数和大小相似,刺激结束时绒促性素β组较安慰剂组观察到12-17 mm中等大小卵泡呈剂量相关减少。
  • 所有绒促性素β剂量组的中等大小(12-17 mm)卵泡数和获卵数(均值范围9.7-11.2)均少于单用促卵泡激素δ组(均值12.5)。
  • 优质囊胚数在促卵泡激素δ组为3.3,绒促性素β各组范围2.1-3.0;4、8和12 μg组移植取消发生率较高,多因无囊胚可移植。

关键数值与推荐

  • 在单用促卵泡激素δ组,持续妊娠率(移植后10-11周)为每启动周期43%、每移植49%;绒促性素β组分别为每启动周期28-39%、每移植38-50%。
  • 不良事件发生率在安慰剂组为48.1%,绒促性素β剂量组为39.6-52.3%。
  • 卵巢过度刺激综合征总体发生率在促卵泡激素δ联合绒促性素β组为2.0-10.3%,低于单用促卵泡激素δ治疗的11.5%。

临床怎么用

  • 促卵泡激素δ组的高持续妊娠率支持在长GnRH激动剂方案中使用个体化促卵泡激素δ剂量。
  • 作者指出需要进一步临床研究评估绒促性素β与促卵泡激素δ最佳比例下的最佳剂量,以开发含FSH和LH活性的新型组合产品用于卵巢刺激。

局限性

  • 试验前对绒促性素β独特糖基化及其相关效力在女性中的影响尚不了解。
  • 需要进一步研究评估绒促性素β在此和/或其他适应症中的最佳剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does addition of choriogonadotropin beta (recombinant CG beta) to follitropin delta increase the number of good-quality blastocysts following ovarian stimulation in a long GnRH agonist protocol? SUMMARY ANSWER: At the doses investigated, the addition of CG beta reduced the number of intermediate follicles and related down-stream parameters including the number of oocytes and blastocysts. WHAT IS KNOWN ALREADY: CG beta is a novel recombinant hCG (rhCG) molecule expressed by a human cell line (PER.C6®) and has a different glycosylation profile compared to urinary hCG or rhCG derived from a Chinese Hamster Ovary (CHO) cell line. In the first-in-human trial, the CG beta pharmacokinetics were similar between men and women. In women, the AUC and the peak serum concentration (Cmax) increased approximately dose proportionally following single and multiple daily doses. In men, a single dose of CG beta provided higher exposure with a longer half-life and proportionately higher testosterone production than CHO cell-derived rhCG. STUDY DESIGN, SIZE, DURATION: This placebo-controlled, double-blind, randomized trial (RAINBOW) was conducted in five European countries to explore the efficacy and safety of CG beta as add-on treatment to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol. Randomization was stratified by centre and age (30-37 and 38-42 years). The primary endpoint was the number of good-quality blastocysts (Grade 3 BB or higher). Subjects were randomized to receive either placebo or 1, 2, 4, 8 or 12 µg CG beta added to the daily individualized follitropin delta dose during ovarian stimulation. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 620 women (30-42 years) with anti-Müllerian hormone (AMH) levels between 5 and 35 pmol/l were randomized in equal proportions to the six treatment groups and 619 subjects started treatment. All 619 subjects were treated with an individualized dose of follitropin delta determined based on AMH (Elecsys AMH Plus Immunoassay) and body weight. Triggering with rhCG was performed when 3 follicles were ≥17 mm but no more than 25 follicles ≥12 mm were reached. MAIN RESULTS AND THE ROLE OF CHANCE: The demographic characteristics were comparable between the six treatment groups and the overall mean age, body weight and AMH were 35.6 ± 3.3 years, 65.3 ± 10.7 kg and 15.3 ± 7.0 pmol/l, respectively. The incidence of cycle cancellation (range 0-2.9%), total follitropin delta dose (mean 112 µg) and duration of stimulation (mean 10 days) were similar across the groups. At stimulation Day 6, the number and size of follicles was similar between the treatment groups, whereas at the end-of-stimulation dose-related decrease of the intermediate follicles between 12 and 17 mm was observed in comparison to the placebo group. In contrast, the number of follicles ≥17 mm was similar between the CG beta dose groups and the placebo group. A reduced number of intermediate follicles (12 to 17 mm) and fewer oocytes (mean range 9.7 to 11.2) were observed for all doses of CG beta compared to the follitropin delta only group (mean 12.5). The mean number of good-quality blastocysts was 3.3 in the follitropin delta group and ranged between 2.1 and 3.0 across the CG beta groups. The incidence of transfer cancellation was higher in the 4, 8 and 12 µg group, mostly as no blastocyst was available for transfer. In the group receiving only follitropin delta, the ongoing pregnancy rate (10-11 weeks after transfer) was 43% per started cycle versus 28-39% in CG beta groups and 49% per transfer versus 38-50% in the CG beta groups. There was no apparent effect of CG beta on the incidence of adverse events, which was 48.1% in the placebo group and 39.6-52.3% in the CG beta dose groups. In line with the number of collected oocytes, the overall ovarian hyperstimulation syndrome incidence remained lower following follitropin delta with CG beta (2.0-10.3%) compared with follitropin delta only treatment (11.5%). Regardless of the dose, CG beta was safe and well-tolerated with low risk of immunogenicity. LIMITATIONS, REASONS FOR CAUTION: The effect of the unique glycosylation of CG beta and its associated potency implications in women were not known prior to this trial. Further studies will be needed to evaluate optimal doses of CG beta for this and/or different indications. WIDER IMPLICATIONS OF THE FINDINGS: The high ongoing pregnancy rate in the follitropin delta group supports the use of individualized follitropin delta dosing in a long GnRH agonist protocol. The addition of CG beta reduced the presence of intermediate follicles with the investigated doses and negatively affected all down-stream parameters. Further clinical research will be needed to assess the optimal dose of CG beta in the optimal ratio to follitropin delta to develop this novel combination product containing both FSH and LH activity for ovarian stimulation. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by Ferring Pharmaceuticals, Copenhagen, Denmark. B.M. and P.L. are employees of Ferring Pharmaceuticals. M.F.S., H.V., C.Y.A., M.F., C.B., A.P. and Y.K. have received institutional clinical trial fees from Ferring Pharmaceuticals. C.B. has received payments for lectures from Organon, Ferring Pharmaceuticals, Merck A/S and Abbott. M.F.S. has received payment for lectures from Ferring Pharmaceuticals. Y.K. has received payment for lectures from Merck and travel support from Gedeon Richter. H.V. has received consulting fees from Oxo and Obseva and travel support from Gedeon Richter, Ferring Pharmaceuticals and Merck. C.Y.A. has received payment for lectures from IBSA, Switzerland. M.F and C.Y.A. were reimbursed as members of the Data Monitoring Board in this trial. M.F. has an issued patent about unitary combination of FSH and hCG (EP1633389). TRIAL REGISTRATION NUMBER: 2017-003810-13 (EudraCT Number). TRIAL REGISTRATION DATE: 21 May 2018. DATE OF FIRST PATIENT’S ENROLMENT: 13 June 2018.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Fernández Sánchez M, Višnová H, Larsson P, et al. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol. Hum Reprod. 2022. PMID: 35451013. doi:10.1093/humrep/deac061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。